EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis.

CONCLUSIONS: EGFR mono-antibody may be a potential modality for locally advanced PSCC patients after chemotherapy failure. Further large-scale clinical studies are needed to elucidate the role of human papillomavirus status and critical gene mutations in the clinical response to EGFR-targeted therapy.
PMID: 30446465 [PubMed - as supplied by publisher]

Source: Urologic Oncology - November 13, 2018 Category: Urology & Nephrology Authors: Huang KB, Liu RY, Peng QH, Li ZS, Jiang LJ, Guo SJ, Zhou QH, Liu TY, Deng CZ, Yao K, Qin ZK, Liu ZW, Li YH, Han H, Zhou FJ Tags: Urol Oncol Source Type: research